• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Expert Perspectives


      Hear from dermatology experts across the UK
      on the following topics:

      Where are we now in atopic dermatitis (AD)?

      Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust

      Clinical overview of RINVOQ: MEASURE UP 1 and 2

      Dr Hamish Hunter, Consultant Dermatologist at Salford Royal NHS Foundation Trust

      Initiating Therapy

      Dr Eirini Merika, Consultant Dermatologist at Chelsea and Westminster Hospital, London

      RINVOQ mode of action in AD 

      Dr Andrew Pink, Consultant Dermatologist at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust

      RINVOQ for treating AD in adolescents

      Dr Jen Sharif, Consultant Dermatologist, Salford Royal NHS Foundation Trust

      The Impact of AD: Patient Stories

      Teena Mackenzie, Biologic, Inflammatory Disease and Research CNS at Royal Berkshire Hospital and Oxford University Hospitals NHS Trust

      1. RINVOQ Summary of Product Characteristics

      UK-RNQD-210309. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com